InfuSystem Holdings, Inc. (AMEX: INFU) Stock Competitors & Peer Comparison
See INFU's competitors and their performance on the AMEX and across the wider stock market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for INFU and its AMEX peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| INFU | $13.94 | -1.41% | 277.4M | 33.98 | $0.41 | N/A |
| ABT | $103.70 | +1.16% | 179.4B | 19.90 | $5.21 | +2.43% |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| MDT | $95.41 | -1.22% | 122B | 17.25 | $5.53 | +2.99% |
| SYK | $307.15 | +0.02% | 117.8B | 22.94 | $13.39 | +1.14% |
| BSX | $45.69 | -0.70% | 66.2B | 14.73 | $3.10 | N/A |
| EW | $89.07 | -1.13% | 51.3B | 32.99 | $2.70 | N/A |
| GEHC | $71.45 | +0.10% | 32.3B | 15.67 | $4.56 | +0.20% |
| DXCM | $77.94 | -0.49% | 29.4B | 30.56 | $2.55 | N/A |
| PHG | $26.89 | +2.52% | 25.8B | 15.38 | $1.75 | +3.68% |
Stock Comparison
Abbott Laboratories (NYSE: ABT)
INFU vs ABT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ABT has a market cap of 179.4B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ABT trades at $103.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ABT's P/E ratio is 19.90. In terms of profitability, INFU's ROE is +0.15%, compared to ABT's ROE of +0.09%. Regarding short-term risk, INFU is similarly volatile compared to ABT. This indicates similar risk in terms of short-term price fluctuations for INFU.Check ABT's competition here
Boston Scientific Corporation (NYSE: BSX-PA)
INFU vs BSX-PA Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, INFU's ROE is +0.15%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, INFU is less volatile compared to BSX-PA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BSX-PA's competition here
Medtronic Plc (NYSE: MDT)
INFU vs MDT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, MDT has a market cap of 122B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while MDT trades at $95.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas MDT's P/E ratio is 17.25. In terms of profitability, INFU's ROE is +0.15%, compared to MDT's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to MDT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MDT's competition here
Stryker Corporation (NYSE: SYK)
INFU vs SYK Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SYK has a market cap of 117.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SYK trades at $307.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SYK's P/E ratio is 22.94. In terms of profitability, INFU's ROE is +0.15%, compared to SYK's ROE of +0.16%. Regarding short-term risk, INFU is more volatile compared to SYK. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SYK's competition here
Boston Scientific Corporation (NYSE: BSX)
INFU vs BSX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BSX has a market cap of 66.2B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BSX trades at $45.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BSX's P/E ratio is 14.73. In terms of profitability, INFU's ROE is +0.15%, compared to BSX's ROE of +0.15%. Regarding short-term risk, INFU is more volatile compared to BSX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BSX's competition here
Edwards Lifesciences Corporation (NYSE: EW)
INFU vs EW Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, EW has a market cap of 51.3B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while EW trades at $89.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas EW's P/E ratio is 32.99. In terms of profitability, INFU's ROE is +0.15%, compared to EW's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to EW. This indicates higher risk in terms of short-term price fluctuations for INFU.Check EW's competition here
GE HealthCare Technologies Inc. (NASDAQ: GEHC)
INFU vs GEHC Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, GEHC has a market cap of 32.3B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while GEHC trades at $71.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas GEHC's P/E ratio is 15.67. In terms of profitability, INFU's ROE is +0.15%, compared to GEHC's ROE of +0.15%. Regarding short-term risk, INFU is less volatile compared to GEHC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GEHC's competition here
DexCom, Inc. (NASDAQ: DXCM)
INFU vs DXCM Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, DXCM has a market cap of 29.4B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while DXCM trades at $77.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas DXCM's P/E ratio is 30.56. In terms of profitability, INFU's ROE is +0.15%, compared to DXCM's ROE of +0.36%. Regarding short-term risk, INFU is more volatile compared to DXCM. This indicates higher risk in terms of short-term price fluctuations for INFU.Check DXCM's competition here
Koninklijke Philips N.V. (NYSE: PHG)
INFU vs PHG Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, PHG has a market cap of 25.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while PHG trades at $26.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas PHG's P/E ratio is 15.38. In terms of profitability, INFU's ROE is +0.15%, compared to PHG's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to PHG. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PHG's competition here
Zimmer Biomet Holdings, Inc. (NYSE: ZBH)
INFU vs ZBH Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ZBH has a market cap of 18.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ZBH trades at $98.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ZBH's P/E ratio is 11.62. In terms of profitability, INFU's ROE is +0.15%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, INFU is more volatile compared to ZBH. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ZBH's competition here
Abiomed, Inc. (NASDAQ: ABMD)
INFU vs ABMD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ABMD's P/E ratio is 65.36. In terms of profitability, INFU's ROE is +0.15%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to ABMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ABMD's competition here
Smith & Nephew plc (NYSE: SNN)
INFU vs SNN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SNN has a market cap of 12.9B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SNN trades at $30.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SNN's P/E ratio is 20.81. In terms of profitability, INFU's ROE is +0.15%, compared to SNN's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to SNN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SNN's competition here
Penumbra, Inc. (NYSE: PEN)
INFU vs PEN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, PEN has a market cap of 12.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while PEN trades at $324.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas PEN's P/E ratio is 84.77. In terms of profitability, INFU's ROE is +0.15%, compared to PEN's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to PEN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check PEN's competition here
ShockWave Medical, Inc. (NASDAQ: SWAV)
INFU vs SWAV Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SWAV's P/E ratio is 78.76. In terms of profitability, INFU's ROE is +0.15%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, INFU is more volatile compared to SWAV. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SWAV's competition here
Align Technology, Inc. (NASDAQ: ALGN)
INFU vs ALGN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ALGN has a market cap of 11B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ALGN trades at $154.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ALGN's P/E ratio is 14.08. In terms of profitability, INFU's ROE is +0.15%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, INFU is more volatile compared to ALGN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ALGN's competition here
Globus Medical, Inc. (NYSE: GMED)
INFU vs GMED Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, GMED has a market cap of 10.9B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while GMED trades at $81.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas GMED's P/E ratio is 18.33. In terms of profitability, INFU's ROE is +0.15%, compared to GMED's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to GMED. This indicates higher risk in terms of short-term price fluctuations for INFU.Check GMED's competition here
Glaukos Corporation (NYSE: GKOS)
INFU vs GKOS Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, GKOS has a market cap of 10.6B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while GKOS trades at $178.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas GKOS's P/E ratio is -208.02. In terms of profitability, INFU's ROE is +0.15%, compared to GKOS's ROE of -0.27%. Regarding short-term risk, INFU is less volatile compared to GKOS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check GKOS's competition here
Insulet Corp. (NASDAQ: PODD)
INFU vs PODD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, PODD has a market cap of 10.3B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while PODD trades at $149.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas PODD's P/E ratio is 25.39. In terms of profitability, INFU's ROE is +0.15%, compared to PODD's ROE of +0.27%. Regarding short-term risk, INFU is less volatile compared to PODD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PODD's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO)
INFU vs BIO Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BIO has a market cap of 9.9B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BIO trades at $369.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BIO's P/E ratio is 39.89. In terms of profitability, INFU's ROE is +0.15%, compared to BIO's ROE of +0.03%. Regarding short-term risk, INFU is less volatile compared to BIO. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BIO's competition here
Bio-Rad Laboratories, Inc. (NYSE: BIO-B)
INFU vs BIO-B Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BIO-B has a market cap of 9.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BIO-B trades at $365.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BIO-B's P/E ratio is -64.41. In terms of profitability, INFU's ROE is +0.15%, compared to BIO-B's ROE of +0.03%. Regarding short-term risk, INFU is more volatile compared to BIO-B. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BIO-B's competition here
Masimo Corporation (NASDAQ: MASI)
INFU vs MASI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while MASI trades at $179.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas MASI's P/E ratio is 44.43. In terms of profitability, INFU's ROE is +0.15%, compared to MASI's ROE of +0.09%. Regarding short-term risk, INFU is more volatile compared to MASI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MASI's competition here
Bruker Corporation (NASDAQ: BRKRP)
INFU vs BRKRP Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BRKRP has a market cap of 8.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BRKRP trades at $421.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BRKRP's P/E ratio is 230.70. In terms of profitability, INFU's ROE is +0.15%, compared to BRKRP's ROE of -0.03%. Regarding short-term risk, INFU is more volatile compared to BRKRP. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BRKRP's competition here
Bruker Corporation (NASDAQ: BRKR)
INFU vs BRKR Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BRKR has a market cap of 8.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BRKR trades at $57.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BRKR's P/E ratio is 28.94. In terms of profitability, INFU's ROE is +0.15%, compared to BRKR's ROE of -0.03%. Regarding short-term risk, INFU is less volatile compared to BRKR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BRKR's competition here
Haemonetics Corporation (NYSE: HAE)
INFU vs HAE Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, HAE has a market cap of 5.4B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while HAE trades at $118.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas HAE's P/E ratio is 23.65. In terms of profitability, INFU's ROE is +0.15%, compared to HAE's ROE of +0.11%. Regarding short-term risk, INFU is less volatile compared to HAE. This indicates lower risk in terms of short-term price fluctuations for INFU.Check HAE's competition here
Inari Medical, Inc. (NASDAQ: NARI)
INFU vs NARI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas NARI's P/E ratio is -59.24. In terms of profitability, INFU's ROE is +0.15%, compared to NARI's ROE of -0.00%. Regarding short-term risk, INFU is more volatile compared to NARI. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NARI's competition here
LivaNova PLC (NASDAQ: LIVN)
INFU vs LIVN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, LIVN has a market cap of 4.4B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while LIVN trades at $80.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas LIVN's P/E ratio is 19.22. In terms of profitability, INFU's ROE is +0.15%, compared to LIVN's ROE of +0.15%. Regarding short-term risk, INFU is more volatile compared to LIVN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check LIVN's competition here
Integer Holdings Corporation (NYSE: ITGR)
INFU vs ITGR Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ITGR has a market cap of 4.3B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ITGR trades at $126.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ITGR's P/E ratio is 19.93. In terms of profitability, INFU's ROE is +0.15%, compared to ITGR's ROE of +0.07%. Regarding short-term risk, INFU is more volatile compared to ITGR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ITGR's competition here
iRhythm Technologies, Inc. (NASDAQ: IRTC)
INFU vs IRTC Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, IRTC has a market cap of 4B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while IRTC trades at $121.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas IRTC's P/E ratio is -282.02. In terms of profitability, INFU's ROE is +0.15%, compared to IRTC's ROE of -0.09%. Regarding short-term risk, INFU is less volatile compared to IRTC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IRTC's competition here
Neogen Corporation (NASDAQ: NEOG)
INFU vs NEOG Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, NEOG has a market cap of 2.7B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while NEOG trades at $12.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas NEOG's P/E ratio is 43.54. In terms of profitability, INFU's ROE is +0.15%, compared to NEOG's ROE of -0.03%. Regarding short-term risk, INFU is less volatile compared to NEOG. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NEOG's competition here
TransMedics Group, Inc. (NASDAQ: TMDX)
INFU vs TMDX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while TMDX trades at $70.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas TMDX's P/E ratio is 35.91. In terms of profitability, INFU's ROE is +0.15%, compared to TMDX's ROE of +0.33%. Regarding short-term risk, INFU is less volatile compared to TMDX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TMDX's competition here
UFP Technologies, Inc. (NASDAQ: UFPT)
INFU vs UFPT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, UFPT has a market cap of 2.3B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while UFPT trades at $295.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas UFPT's P/E ratio is 30.21. In terms of profitability, INFU's ROE is +0.15%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, INFU is less volatile compared to UFPT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check UFPT's competition here
AxoGen, Inc. (NASDAQ: AXGN)
INFU vs AXGN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, AXGN has a market cap of 2.2B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while AXGN trades at $38.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas AXGN's P/E ratio is 100.16. In terms of profitability, INFU's ROE is +0.15%, compared to AXGN's ROE of -0.18%. Regarding short-term risk, INFU is less volatile compared to AXGN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AXGN's competition here
NuVasive, Inc. (NASDAQ: NUVA)
INFU vs NUVA Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas NUVA's P/E ratio is 75.00. In terms of profitability, INFU's ROE is +0.15%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, INFU is less volatile compared to NUVA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NUVA's competition here
Inspire Medical Systems, Inc. (NYSE: INSP)
INFU vs INSP Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, INSP has a market cap of 2.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while INSP trades at $71.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas INSP's P/E ratio is 31.32. In terms of profitability, INFU's ROE is +0.15%, compared to INSP's ROE of +0.18%. Regarding short-term risk, INFU is less volatile compared to INSP. This indicates lower risk in terms of short-term price fluctuations for INFU.Check INSP's competition here
Establishment Labs Holdings Inc. (NASDAQ: ESTA)
INFU vs ESTA Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ESTA has a market cap of 1.9B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ESTA trades at $63.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ESTA's P/E ratio is -50.63. In terms of profitability, INFU's ROE is +0.15%, compared to ESTA's ROE of -2.04%. Regarding short-term risk, INFU is less volatile compared to ESTA. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ESTA's competition here
Butterfly Network, Inc. (NYSE: BFLY)
INFU vs BFLY Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BFLY has a market cap of 1.8B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BFLY trades at $6.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BFLY's P/E ratio is -28.17. In terms of profitability, INFU's ROE is +0.15%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, INFU is less volatile compared to BFLY. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BFLY's competition here
Alphatec Holdings, Inc. (NASDAQ: ATEC)
INFU vs ATEC Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ATEC has a market cap of 1.7B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ATEC trades at $11.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ATEC's P/E ratio is -185.17. In terms of profitability, INFU's ROE is +0.15%, compared to ATEC's ROE of -8.19%. Regarding short-term risk, INFU is less volatile compared to ATEC. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ATEC's competition here
Novocure Ltd (NASDAQ: NVCR)
INFU vs NVCR Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, NVCR has a market cap of 1.7B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while NVCR trades at $14.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas NVCR's P/E ratio is -11.29. In terms of profitability, INFU's ROE is +0.15%, compared to NVCR's ROE of -0.44%. Regarding short-term risk, INFU is less volatile compared to NVCR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NVCR's competition here
CONMED Corporation (NYSE: CNMD)
INFU vs CNMD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CNMD has a market cap of 1.5B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CNMD trades at $49.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CNMD's P/E ratio is 10.80. In terms of profitability, INFU's ROE is +0.15%, compared to CNMD's ROE of +0.06%. Regarding short-term risk, INFU is less volatile compared to CNMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CNMD's competition here
Heska Corporation (NASDAQ: HSKA)
INFU vs HSKA Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas HSKA's P/E ratio is -62.49. In terms of profitability, INFU's ROE is +0.15%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, INFU is more volatile compared to HSKA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check HSKA's competition here
Enovis Corporation (NYSE: ENOV)
INFU vs ENOV Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ENOV has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ENOV trades at $21.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ENOV's P/E ratio is 6.04. In terms of profitability, INFU's ROE is +0.15%, compared to ENOV's ROE of -0.68%. Regarding short-term risk, INFU is less volatile compared to ENOV. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ENOV's competition here
Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
INFU vs TNDM Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, TNDM has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while TNDM trades at $17.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas TNDM's P/E ratio is -18.74. In terms of profitability, INFU's ROE is +0.15%, compared to TNDM's ROE of -0.46%. Regarding short-term risk, INFU is less volatile compared to TNDM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TNDM's competition here
Avanos Medical, Inc. (NYSE: AVNS)
INFU vs AVNS Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while AVNS trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas AVNS's P/E ratio is 27.77. In terms of profitability, INFU's ROE is +0.15%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, INFU is more volatile compared to AVNS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check AVNS's competition here
PROCEPT BioRobotics Corporation (NASDAQ: PRCT)
INFU vs PRCT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, PRCT has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while PRCT trades at $19.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas PRCT's P/E ratio is -10.29. In terms of profitability, INFU's ROE is +0.15%, compared to PRCT's ROE of -0.31%. Regarding short-term risk, INFU is less volatile compared to PRCT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PRCT's competition here
Artivion, Inc. (NYSE: AORT)
INFU vs AORT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, AORT has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while AORT trades at $23.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas AORT's P/E ratio is 38.82. In terms of profitability, INFU's ROE is +0.15%, compared to AORT's ROE of -0.01%. Regarding short-term risk, INFU is less volatile compared to AORT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AORT's competition here
Lumexa Imaging Holdings, Inc. Common Stock (NASDAQ: LMRI)
INFU vs LMRI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, LMRI has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while LMRI trades at $11.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas LMRI's P/E ratio is -22.69. In terms of profitability, INFU's ROE is +0.15%, compared to LMRI's ROE of -0.06%. Regarding short-term risk, INFU is less volatile compared to LMRI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check LMRI's competition here
Silk Road Medical, Inc (NASDAQ: SILK)
INFU vs SILK Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SILK's P/E ratio is -18.96. In terms of profitability, INFU's ROE is +0.15%, compared to SILK's ROE of -0.35%. Regarding short-term risk, INFU is more volatile compared to SILK. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SILK's competition here
Paragon 28, Inc. (NYSE: FNA)
INFU vs FNA Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas FNA's P/E ratio is -19.83. In terms of profitability, INFU's ROE is +0.15%, compared to FNA's ROE of -0.35%. Regarding short-term risk, INFU is more volatile compared to FNA. This indicates higher risk in terms of short-term price fluctuations for INFU.Check FNA's competition here
IRadimed Corporation (NASDAQ: IRMD)
INFU vs IRMD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, IRMD has a market cap of 1.1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while IRMD trades at $85.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas IRMD's P/E ratio is 43.13. In terms of profitability, INFU's ROE is +0.15%, compared to IRMD's ROE of +0.23%. Regarding short-term risk, INFU is less volatile compared to IRMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IRMD's competition here
CeriBell, Inc. (NASDAQ: CBLL)
INFU vs CBLL Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CBLL has a market cap of 1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CBLL trades at $27.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CBLL's P/E ratio is -15.41. In terms of profitability, INFU's ROE is +0.15%, compared to CBLL's ROE of -0.45%. Regarding short-term risk, INFU is less volatile compared to CBLL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CBLL's competition here
Bioventus Inc. (NASDAQ: BVS)
INFU vs BVS Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BVS has a market cap of 1B. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BVS trades at $14.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BVS's P/E ratio is 19.68. In terms of profitability, INFU's ROE is +0.15%, compared to BVS's ROE of +0.28%. Regarding short-term risk, INFU is more volatile compared to BVS. This indicates higher risk in terms of short-term price fluctuations for INFU.Check BVS's competition here
SI-BONE, Inc. (NASDAQ: SIBN)
INFU vs SIBN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SIBN has a market cap of 962.7M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SIBN trades at $21.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SIBN's P/E ratio is -63.18. In terms of profitability, INFU's ROE is +0.15%, compared to SIBN's ROE of -0.08%. Regarding short-term risk, INFU is less volatile compared to SIBN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SIBN's competition here
Integra LifeSciences Holdings Corporation (NASDAQ: IART)
INFU vs IART Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, IART has a market cap of 926.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while IART trades at $11.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas IART's P/E ratio is 5.05. In terms of profitability, INFU's ROE is +0.15%, compared to IART's ROE of +0.02%. Regarding short-term risk, INFU is less volatile compared to IART. This indicates lower risk in terms of short-term price fluctuations for INFU.Check IART's competition here
Beta Bionics, Inc. (NASDAQ: BBNX)
INFU vs BBNX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BBNX has a market cap of 862M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BBNX trades at $19.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BBNX's P/E ratio is -11.61. In terms of profitability, INFU's ROE is +0.15%, compared to BBNX's ROE of -0.26%. Regarding short-term risk, INFU is less volatile compared to BBNX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BBNX's competition here
Cardiovascular Systems, Inc. (NASDAQ: CSII)
INFU vs CSII Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CSII's P/E ratio is -20.83. In terms of profitability, INFU's ROE is +0.15%, compared to CSII's ROE of -0.14%. Regarding short-term risk, INFU is more volatile compared to CSII. This indicates higher risk in terms of short-term price fluctuations for INFU.Check CSII's competition here
AdaptHealth Corp. (NASDAQ: AHCO)
INFU vs AHCO Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, AHCO has a market cap of 820.8M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while AHCO trades at $6.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas AHCO's P/E ratio is 12.29. In terms of profitability, INFU's ROE is +0.15%, compared to AHCO's ROE of -0.15%. Regarding short-term risk, INFU is less volatile compared to AHCO. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AHCO's competition here
InMode Ltd. (NASDAQ: INMD)
INFU vs INMD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, INMD has a market cap of 803.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while INMD trades at $13.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas INMD's P/E ratio is 9.70. In terms of profitability, INFU's ROE is +0.15%, compared to INMD's ROE of +0.12%. Regarding short-term risk, INFU is more volatile compared to INMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check INMD's competition here
Varex Imaging Corporation (NASDAQ: VREX)
INFU vs VREX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, VREX has a market cap of 782.2M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while VREX trades at $18.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas VREX's P/E ratio is 19.39. In terms of profitability, INFU's ROE is +0.15%, compared to VREX's ROE of +0.05%. Regarding short-term risk, INFU is more volatile compared to VREX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check VREX's competition here
Picard Medical, Inc. (AMEX: PMI)
INFU vs PMI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, PMI has a market cap of 758.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while PMI trades at $7.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas PMI's P/E ratio is -6.16. In terms of profitability, INFU's ROE is +0.15%, compared to PMI's ROE of -9.31%. Regarding short-term risk, INFU is less volatile compared to PMI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PMI's competition here
Cytek Biosciences, Inc. (NASDAQ: CTKB)
INFU vs CTKB Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CTKB has a market cap of 726.6M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CTKB trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CTKB's P/E ratio is -29.61. In terms of profitability, INFU's ROE is +0.15%, compared to CTKB's ROE of -0.24%. Regarding short-term risk, INFU is less volatile compared to CTKB. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CTKB's competition here
Pacific Biosciences of California, Inc. (NASDAQ: PACB)
INFU vs PACB Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, PACB has a market cap of 655.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while PACB trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas PACB's P/E ratio is -5.15. In terms of profitability, INFU's ROE is +0.15%, compared to PACB's ROE of -49.62%. Regarding short-term risk, INFU is less volatile compared to PACB. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PACB's competition here
OrthoPediatrics Corp. (NASDAQ: KIDS)
INFU vs KIDS Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, KIDS has a market cap of 638.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while KIDS trades at $24.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas KIDS's P/E ratio is -20.74. In terms of profitability, INFU's ROE is +0.15%, compared to KIDS's ROE of -0.12%. Regarding short-term risk, INFU is less volatile compared to KIDS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check KIDS's competition here
Surmodics, Inc. (NASDAQ: SRDX)
INFU vs SRDX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SRDX's P/E ratio is -34.66. In terms of profitability, INFU's ROE is +0.15%, compared to SRDX's ROE of -0.10%. Regarding short-term risk, INFU is more volatile compared to SRDX. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SRDX's competition here
Apollo Endosurgery, Inc. (NASDAQ: APEN)
INFU vs APEN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas APEN's P/E ratio is -9.43. In terms of profitability, INFU's ROE is +0.15%, compared to APEN's ROE of -0.85%. Regarding short-term risk, INFU is more volatile compared to APEN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check APEN's competition here
Anteris Technologies Global Corp. (NASDAQ: AVR)
INFU vs AVR Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, AVR has a market cap of 571.6M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while AVR trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas AVR's P/E ratio is -3.02. In terms of profitability, INFU's ROE is +0.15%, compared to AVR's ROE of -0.78%. Regarding short-term risk, INFU is less volatile compared to AVR. This indicates lower risk in terms of short-term price fluctuations for INFU.Check AVR's competition here
ZimVie Inc. (NASDAQ: ZIMV)
INFU vs ZIMV Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, INFU's ROE is +0.15%, compared to ZIMV's ROE of -0.07%. Regarding short-term risk, INFU is more volatile compared to ZIMV. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ZIMV's competition here
Tactile Systems Technology, Inc. (NASDAQ: TCMD)
INFU vs TCMD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, TCMD has a market cap of 535.5M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while TCMD trades at $23.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas TCMD's P/E ratio is 21.89. In terms of profitability, INFU's ROE is +0.15%, compared to TCMD's ROE of +0.11%. Regarding short-term risk, INFU is more volatile compared to TCMD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check TCMD's competition here
Delcath Systems, Inc. (NASDAQ: DCTH)
INFU vs DCTH Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, DCTH has a market cap of 500.4M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while DCTH trades at $14.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas DCTH's P/E ratio is 1442.00. In terms of profitability, INFU's ROE is +0.15%, compared to DCTH's ROE of +0.00%. Regarding short-term risk, INFU is less volatile compared to DCTH. This indicates lower risk in terms of short-term price fluctuations for INFU.Check DCTH's competition here
Sight Sciences, Inc. (NASDAQ: SGHT)
INFU vs SGHT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SGHT has a market cap of 495.2M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SGHT trades at $8.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SGHT's P/E ratio is -16.05. In terms of profitability, INFU's ROE is +0.15%, compared to SGHT's ROE of -0.51%. Regarding short-term risk, INFU is less volatile compared to SGHT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SGHT's competition here
Cerus Corporation (NASDAQ: CERS)
INFU vs CERS Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CERS has a market cap of 469.6M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CERS trades at $2.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CERS's P/E ratio is -77.41. In terms of profitability, INFU's ROE is +0.15%, compared to CERS's ROE of -0.10%. Regarding short-term risk, INFU is less volatile compared to CERS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CERS's competition here
SS Innovations International, Inc. (NASDAQ: SSII)
INFU vs SSII Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SSII has a market cap of 457.1M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SSII trades at $2.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SSII's P/E ratio is -38.00. In terms of profitability, INFU's ROE is +0.15%, compared to SSII's ROE of -0.27%. Regarding short-term risk, INFU is less volatile compared to SSII. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SSII's competition here
NeuroPace, Inc. (NASDAQ: NPCE)
INFU vs NPCE Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, NPCE has a market cap of 443.1M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while NPCE trades at $12.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas NPCE's P/E ratio is -22.65. In terms of profitability, INFU's ROE is +0.15%, compared to NPCE's ROE of -1.20%. Regarding short-term risk, INFU is less volatile compared to NPCE. This indicates lower risk in terms of short-term price fluctuations for INFU.Check NPCE's competition here
Senseonics Holdings, Inc. (NASDAQ: SENS)
INFU vs SENS Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SENS has a market cap of 397.1M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SENS trades at $7.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SENS's P/E ratio is -3.37. In terms of profitability, INFU's ROE is +0.15%, compared to SENS's ROE of -1.66%. Regarding short-term risk, INFU is less volatile compared to SENS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check SENS's competition here
Orthofix Medical Inc. (NASDAQ: OFIX)
INFU vs OFIX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, OFIX has a market cap of 396.5M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while OFIX trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas OFIX's P/E ratio is -6.39. In terms of profitability, INFU's ROE is +0.15%, compared to OFIX's ROE of -0.14%. Regarding short-term risk, INFU is less volatile compared to OFIX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check OFIX's competition here
Avita Medical Inc. (NASDAQ: RCEL)
INFU vs RCEL Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, RCEL has a market cap of 385.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while RCEL trades at $15.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas RCEL's P/E ratio is -10.77. In terms of profitability, INFU's ROE is +0.15%, compared to RCEL's ROE of +2.32%. Regarding short-term risk, INFU is less volatile compared to RCEL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check RCEL's competition here
CapsoVision, Inc. (NASDAQ: CV)
INFU vs CV Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CV has a market cap of 371.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CV trades at $6.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CV's P/E ratio is -11.10. In terms of profitability, INFU's ROE is +0.15%, compared to CV's ROE of -1.78%. Regarding short-term risk, INFU is less volatile compared to CV. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CV's competition here
Semler Scientific, Inc. (NASDAQ: SMLR)
INFU vs SMLR Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas SMLR's P/E ratio is 3.92. In terms of profitability, INFU's ROE is +0.15%, compared to SMLR's ROE of +0.20%. Regarding short-term risk, INFU is more volatile compared to SMLR. This indicates higher risk in terms of short-term price fluctuations for INFU.Check SMLR's competition here
ClearPoint Neuro, Inc. (NASDAQ: CLPT)
INFU vs CLPT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CLPT has a market cap of 278.8M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CLPT trades at $9.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CLPT's P/E ratio is -7.75. In terms of profitability, INFU's ROE is +0.15%, compared to CLPT's ROE of -1.88%. Regarding short-term risk, INFU is less volatile compared to CLPT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CLPT's competition here
Quantum-Si incorporated (NASDAQ: QSI)
INFU vs QSI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, QSI has a market cap of 278.5M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while QSI trades at $1.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas QSI's P/E ratio is -3.04. In terms of profitability, INFU's ROE is +0.15%, compared to QSI's ROE of -0.47%. Regarding short-term risk, INFU is less volatile compared to QSI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check QSI's competition here
Treace Medical Concepts, Inc. (NASDAQ: TMCI)
INFU vs TMCI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, TMCI has a market cap of 277.7M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while TMCI trades at $4.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas TMCI's P/E ratio is -4.54. In terms of profitability, INFU's ROE is +0.15%, compared to TMCI's ROE of -0.74%. Regarding short-term risk, INFU is less volatile compared to TMCI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TMCI's competition here
Monogram Orthopaedics, Inc. (NASDAQ: MGRM)
INFU vs MGRM Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas MGRM's P/E ratio is -12.00. In terms of profitability, INFU's ROE is +0.15%, compared to MGRM's ROE of -1.17%. Regarding short-term risk, INFU is more volatile compared to MGRM. This indicates higher risk in terms of short-term price fluctuations for INFU.Check MGRM's competition here
Nevro Corp. (NYSE: NVRO)
INFU vs NVRO Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas NVRO's P/E ratio is -1.91. In terms of profitability, INFU's ROE is +0.15%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, INFU is more volatile compared to NVRO. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NVRO's competition here
TriSalus Life Sciences, Inc. (NASDAQ: TLSI)
INFU vs TLSI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, TLSI has a market cap of 221.1M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while TLSI trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas TLSI's P/E ratio is -2.14. In terms of profitability, INFU's ROE is +0.15%, compared to TLSI's ROE of +2.74%. Regarding short-term risk, INFU is less volatile compared to TLSI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check TLSI's competition here
Electromed, Inc. (AMEX: ELMD)
INFU vs ELMD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ELMD has a market cap of 218.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ELMD trades at $26.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ELMD's P/E ratio is 20.11. In terms of profitability, INFU's ROE is +0.15%, compared to ELMD's ROE of +0.23%. Regarding short-term risk, INFU is less volatile compared to ELMD. This indicates lower risk in terms of short-term price fluctuations for INFU.Check ELMD's competition here
Profound Medical Corp. (NASDAQ: PROF)
INFU vs PROF Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, PROF has a market cap of 210.8M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while PROF trades at $5.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas PROF's P/E ratio is -5.89. In terms of profitability, INFU's ROE is +0.15%, compared to PROF's ROE of -0.56%. Regarding short-term risk, INFU is less volatile compared to PROF. This indicates lower risk in terms of short-term price fluctuations for INFU.Check PROF's competition here
RxSight, Inc. (NASDAQ: RXST)
INFU vs RXST Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, RXST has a market cap of 208.8M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while RXST trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas RXST's P/E ratio is -4.44. In terms of profitability, INFU's ROE is +0.15%, compared to RXST's ROE of -0.17%. Regarding short-term risk, INFU is more volatile compared to RXST. This indicates higher risk in terms of short-term price fluctuations for INFU.Check RXST's competition here
BioSig Technologies, Inc. (NASDAQ: BSGM)
INFU vs BSGM Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas BSGM's P/E ratio is -5.81. In terms of profitability, INFU's ROE is +0.15%, compared to BSGM's ROE of +6.96%. Regarding short-term risk, INFU is less volatile compared to BSGM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check BSGM's competition here
Inogen, Inc. (NASDAQ: INGN)
INFU vs INGN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, INGN has a market cap of 188.4M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while INGN trades at $7.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas INGN's P/E ratio is -7.80. In terms of profitability, INFU's ROE is +0.15%, compared to INGN's ROE of -0.13%. Regarding short-term risk, INFU is less volatile compared to INGN. This indicates lower risk in terms of short-term price fluctuations for INFU.Check INGN's competition here
Perspective Therapeutics, Inc. (AMEX: CATX)
INFU vs CATX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, CATX has a market cap of 182.6M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while CATX trades at $1.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas CATX's P/E ratio is -1.20. In terms of profitability, INFU's ROE is +0.15%, compared to CATX's ROE of -0.42%. Regarding short-term risk, INFU is less volatile compared to CATX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check CATX's competition here
Xylo Technologies Ltd. (NASDAQ: MDGS)
INFU vs MDGS Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas MDGS's P/E ratio is -0.27. In terms of profitability, INFU's ROE is +0.15%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, INFU is less volatile compared to MDGS. This indicates lower risk in terms of short-term price fluctuations for INFU.Check MDGS's competition here
Quipt Home Medical Corp. (NASDAQ: QIPT)
INFU vs QIPT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas QIPT's P/E ratio is -15.87. In terms of profitability, INFU's ROE is +0.15%, compared to QIPT's ROE of -0.08%. Regarding short-term risk, INFU is more volatile compared to QIPT. This indicates higher risk in terms of short-term price fluctuations for INFU.Check QIPT's competition here
Neuronetics, Inc. (NASDAQ: STIM)
INFU vs STIM Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, STIM has a market cap of 160.8M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while STIM trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas STIM's P/E ratio is -4.80. In terms of profitability, INFU's ROE is +0.15%, compared to STIM's ROE of -1.51%. Regarding short-term risk, INFU is less volatile compared to STIM. This indicates lower risk in terms of short-term price fluctuations for INFU.Check STIM's competition here
EDAP TMS S.A. American Depositary Shares (NASDAQ: FOCL)
INFU vs FOCL Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, FOCL has a market cap of 156.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while FOCL trades at $4.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas FOCL's P/E ratio is -4.03. In terms of profitability, INFU's ROE is +0.15%, compared to FOCL's ROE of -2.90%. Regarding short-term risk, INFU is less volatile compared to FOCL. This indicates lower risk in terms of short-term price fluctuations for INFU.Check FOCL's competition here
Quanterix Corporation (NASDAQ: QTRX)
INFU vs QTRX Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, QTRX has a market cap of 135.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while QTRX trades at $2.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas QTRX's P/E ratio is -1.13. In terms of profitability, INFU's ROE is +0.15%, compared to QTRX's ROE of -0.44%. Regarding short-term risk, INFU is less volatile compared to QTRX. This indicates lower risk in terms of short-term price fluctuations for INFU.Check QTRX's competition here
Owlet, Inc. (NYSE: OWLT)
INFU vs OWLT Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, OWLT has a market cap of 120.4M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while OWLT trades at $4.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas OWLT's P/E ratio is -29.43. In terms of profitability, INFU's ROE is +0.15%, compared to OWLT's ROE of -0.50%. Regarding short-term risk, INFU is less volatile compared to OWLT. This indicates lower risk in terms of short-term price fluctuations for INFU.Check OWLT's competition here
iCAD, Inc. (NASDAQ: ICAD)
INFU vs ICAD Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ICAD has a market cap of 106.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ICAD trades at $3.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ICAD's P/E ratio is -20.37. In terms of profitability, INFU's ROE is +0.15%, compared to ICAD's ROE of -0.18%. Regarding short-term risk, INFU is more volatile compared to ICAD. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ICAD's competition here
Hancock Jaffe Laboratories (NASDAQ: HJLI)
INFU vs HJLI Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, HJLI has a market cap of 98.3M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while HJLI trades at $10.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas HJLI's P/E ratio is N/A. In terms of profitability, INFU's ROE is +0.15%, compared to HJLI's ROE of -0.62%. Regarding short-term risk, INFU is less volatile compared to HJLI. This indicates lower risk in terms of short-term price fluctuations for INFU.Check HJLI's competition here
Asensus Surgical, Inc. (AMEX: ASXC)
INFU vs ASXC Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, ASXC has a market cap of 94.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while ASXC trades at $0.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas ASXC's P/E ratio is -1.12. In terms of profitability, INFU's ROE is +0.15%, compared to ASXC's ROE of -1.18%. Regarding short-term risk, INFU is more volatile compared to ASXC. This indicates higher risk in terms of short-term price fluctuations for INFU.Check ASXC's competition here
Neovasc Inc. (NASDAQ: NVCN)
INFU vs NVCN Comparison October 2026
InfuSystem Holdings, Inc. (AMEX: INFU) plays a significant role within the Healthcare sector. Its performance on the AMEX reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, INFU stands at 277.4M. In comparison, NVCN has a market cap of 82.9M. Regarding current trading prices, INFU is priced at $13.94 on the AMEX, while NVCN trades at $30.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
INFU currently has a P/E ratio of 33.98, whereas NVCN's P/E ratio is -1.99. In terms of profitability, INFU's ROE is +0.15%, compared to NVCN's ROE of -1.21%. Regarding short-term risk, INFU is more volatile compared to NVCN. This indicates higher risk in terms of short-term price fluctuations for INFU.Check NVCN's competition here